Quarterly ResultMay 5, 2026, 04:14 PM
Myriad Genetics Q1 Revenue $200.4M; Reiterates FY26 Guidance
AI Summary
Myriad Genetics reported first quarter 2026 financial results, with revenue increasing 2% year-over-year to $200.4 million. The company posted a GAAP net loss of $34.1 million, or $0.36 per share, and an adjusted loss per share of $0.09. Despite a decline in Prenatal Health, the Cancer Care Continuum and Mental Health segments showed strong growth, and the company reiterated its full-year 2026 financial guidance, reflecting ongoing progress and new product launches.
Key Highlights
- Q1 2026 revenue was $200.4 million, a 2% increase year-over-year.
- GAAP net loss for Q1 2026 was $34.1 million, or $0.36 per share.
- Adjusted loss per share was $0.09 and adjusted EBITDA was $(4.5) million.
- Cancer Care Continuum revenue grew 4% to $120.2 million, with volume up 13% YoY.
- Mental Health revenue increased 24% to $38.3 million, with volume up 7% YoY.
- Prenatal Health revenue declined 15% to $41.9 million, with volume down 12% YoY.
- Launched Precise Molecular Residual Disease (MRD) and received FDA approval for MyChoice CDx test.
- Reiterated full-year 2026 revenue guidance of $860-$880 million and adjusted EBITDA of $37-$49 million.